Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Knopp Biosciences
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Austria, Brazil, Bulgaria, Canada, Colombia, Czech Republic, Georgia, Germany, Hungary, Italy, Korea, Lithuania, Macedonia, Mexico, Poland, Romania, Serbia, South Africa, South Korea, Spain, United Kingdom, United States
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Asthma|Pulmonary Eosinophilia
Phase 2: Chronic Obstructive Pulmonary Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
EXHALE-5 | P3 |
Enrolling by invitation |
Pulmonary Eosinophilia|Asthma |
2027-06-01 |
|
jRCT2031240072 | P3 |
Not yet recruiting |
Asthma |
2026-12-11 |
|
EXHALE-2 | P3 |
Recruiting |
Asthma|Pulmonary Eosinophilia |
2026-06-01 |
|
EXHALE-3 | P3 |
Recruiting |
Pulmonary Eosinophilia|Asthma |
2026-06-01 |